



• State-of-the-art multimodal array of sensors that will provide **real time home monitoring** of critical vital and electrophysiological, hemodynamic and chemical signs, physical activity levels and transthoracic impedance data, in chronic heart failure patients.



## Heart Failure (HF)

- Worldwide HF incidence is increasing in parallel to cardiovascular risk factor
- Portugal shows similar trends
- On our Center, near 47% of internal medicine admissions are due to HF



## Heart Failure (HF)

GDH	Designação GDH	Qtd. Episódios	% no total de episódios	% Acumulada
640	Recém-nascido, peso ao nascer > 2499g, normal ou com outros problemas	57022	7,09%	7,09%
560	Parto vaginal	46936	5,83%	12,92%
139	Outras pneumonias	33846	4,21%	17,12%
194	Insuficiência cardíaca	21048	2,62%	19,74%
540	Parto por cesariana	19111	2,37%	22,11%
463	Infeções do rim e/ou vias urinárias	18318	2,28%	24,39%
45	Acidente vascular cerebral e/ou oclusão pré-cerebral com enfarte	16688	2,07%	26,46%
144	Sinais, sintomas e/ou diagnósticos minor respiratórios	14617	1,82%	28,28%
263	Colecistectomia laparoscópica	10028	1,25%	29,52%
308	Procedimentos na anca e/ou fémur por traumatismo exceto substituição da articulação	9209	1,14%	30,67%
Total de episódios		804815	100,00%	100,00%


Fonte: BIMH

30% of deaths among internal medicine patients relate to chronic HF decompensation.

Mortality rates of HF patients needing hospitalization are remarkable, and at our center is aproximately 15%



## MONITORIA and GENICA project



#### **MONITORIA**

- Real-time monitoring of critical variables
- Patient Emergency dispatch Physician communication enabler **MONI**
- Improve quality of life and reduce morbidity/mortality
- Generate data for future research

#### **GENICA**

- Characterize the demographics of heart failure in Northern Portugal
- Development of a cost-effective algorithm to heart failure approach
- Development of a remote monitoring device
- Development of a drug disposal device to each patient
- Multidisciplinary approach to HF







Grupo de Estudos
Normalizando a abordagen
da Insuficiência Cardíaca



## MONITORIA - sensors










## MONITORIA - vest





#### Transthoracic impedance – net lung impedance

- Net lung impedance = transthoracic impedance chest wall impedance

#### **EKG** data

• ↓ Heart rate variability + elevated heart rate ← ↑ mortality and hospitalization [Floras JS, 2009; BEAUTIFUL investigators, Fox K et al, 2008]

T wave heterogeneity + electrical conduction abnormalities + *de novo* arrythmias 

↑ mortality and hospitalization [Zizek D et al, 2012; Tolppanen et al, 2016]



#### Oximetry

- Eight photodiodes + 2 LEDs
- Peripheral desaturation alarm

#### Photoplethysmography (PPG)

- Impedance cardiography + pulse transit time (pulse wave velocity) = Systemic arterial blood pressure (SBP) + cardiac parameters
- SBP alarm
- Pre-ejection period = therapy monitoring





#### Right atrial (RAP) and left atrial pressures (LAP)

- Measured by near-infrared spectroscopy (2 sensors)
- ↑ RAP = ↑ congestion, worse outcome [SICA-HF program, Pellicori P et al, 2017]
- LAP = guide to therapeutic changes, still in research [LAP-Top-HF study, 2016]

#### Skin sodium content

- Microfluidic patch with chemical transducers
- Still not fully evaluated in HF MONITORIA pilot-study
  - Healthy individuals vs HF individuals





#### Gyroscope / Accelerometer


- Moderate levels of physical activity (PA) = ↓ risk of HF + ↓ all-cause mortality in HF [Rahman | et al, 2015; HF-ACTION, Piña | L et al, 2014]
- Monitoring cardiovascular fitness + PA alarm





MONITORIA - operating mode





- 1. New onset of **atrial fibrillation**, atrial fibrillation with rapid ventricular rate, sustained **ventricular tachycardia**, **ventricular fibrillation**;
- 2. Electric conduction pauses ≥ 2 secs or complete atrioventricular block. *De novo* right bundle branch block;
- 3. A **2mm rise in ST segment** at two out of three leads of each group (limb or precordial leads) being highly suspicious of myocardial ischemia;
- 4. **Heart rate ≤ 40bpm and ≥ 120bpm**, lasting more than 5 min, and no (or minimal) physical activity detected.
- 5. **Peripheral oxygen saturation ≤89%,** lasting more than 5 min.
- 6. Instantaneous lung impedance  $\leq$  100%, in three consecutive measurements, or  $\Delta$ LIR <18%.
- 7. Systolic blood pressure  $\leq$  70mmHg or  $\geq$  200mmHg; and/or diastolic blood pressure  $\leq$  35mmHg or  $\geq$  100mmHg, lasting at least 5 min.
- 8. Right atrial pressure ≥ 8mmHg in three consecutive measurements.
- 9. **Left atrial pressure ≥ 12mmHg** in three consecutive measurements.





## MONITORIA - economic analysis

- Target population: severe HF patients (estimated 27000 in 2027) [R. C. Ferreira et al, 2015]
- Price (extrapolated): close to 1000 €; renting price: 50 €/month
- Patient life expectancy after 1st hospitalization = 5 years [D. A. Alter et al, 2012]
- Overall price = 3000 €
- Readmission decrease = about 34% = ↓ 3800 € per patient [D. A. Alter et al, 2012]
- Total net balance: ↓ 800 € in expenditures per patient





### MONITORIA - conclusion

- Non-invasive multi-sensor wearable device
- Huge amount of data collected
- Capable of improving survival and quality of life to its wearer
- Economically viable
- Future-proof:
  - Future options: defibrillator; external pacemaker
    - Minimization
  - Al software to improve early pattern recognition

